Literature DB >> 25261679

Lack of association between LEPR Q223R polymorphisms and cancer susceptibility: evidence from a meta-analysis.

Pengcheng Liu1, Hui Shi, Run Liu, Yunji Yang, Yong Yang, Changjia Huang, Hexi Shu, Jinpeng Gong, Ming Cai.   

Abstract

PURPOSE: The results from the published studies on the association between LEPR genetic polymorphisms and cancer risk are conflicting. The common LEPR Q223R genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancer. However, the association between LEPR Q223R genetic polymorphism and cancer risk remains inconclusive.
METHODS: To better understand the role of LEPR Q223R genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 9139 cases and 11282 controls.
RESULTS: Overall, the LEPR Q223R genetic polymorphism did not significantly affect the risk of cancer. In the stratified analysis, there was no significant association of LEPR Q223R variant with breast cancer, colorectal cancer and non-Hodgkin's lymphoma (NHL) under any models. Moreover, significantly increased risks were found in Asian and African in all genetic models tested. When stratified by study design, no significantly increased susceptibility to cancer was found among any studies. No significantly differences in sample size in cases were found among genotypes.
CONCLUSIONS: These findings suggested lack of association between LEPR Q223R polymorphisms and cancer susceptibility, but the LEPR Q223R genetic polymorphism may increase the susceptibility to cancers in Asian and African individuals. Large, well designed epidemiological studies are needed to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25261679

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  5 in total

1.  Plasma Leptin Levels and Risk of Incident Cancer: Results from the Dallas Heart Study.

Authors:  Arjun Gupta; Yehuda Herman; Colby Ayers; Muhammad S Beg; Susan G Lakoski; Shuaib M Abdullah; David H Johnson; Ian J Neeland
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

2.  Investigation of TCF7L2, LEP and LEPR polymorphisms with esophageal squamous cell carcinomas.

Authors:  Hao Qiu; Xunting Lin; Weifeng Tang; Chao Liu; Yu Chen; Hao Ding; Mingqiang Kang; Shuchen Chen
Journal:  Oncotarget       Date:  2017-11-17

Review 3.  Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: evidence from a meta-analysis and pooled-review.

Authors:  Meng-Bo Hu; Hua Xu; Ji-Meng Hu; Wen-Hui Zhu; Tian Yang; Hao-Wen Jiang; Qiang Ding
Journal:  Oncotarget       Date:  2016-12-06

4.  Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35936 subjects.

Authors:  Guoxiang Rong; Weifeng Tang; Yafeng Wang; Hao Qiu; Shuchen Chen
Journal:  Biosci Rep       Date:  2019-06-28       Impact factor: 3.840

5.  Association of Single Nucleotide Polymorphism LEP-R c.668A>G (p.Gln223Arg, rs1137101) of leptin receptor gene with endometrial cancer.

Authors:  Jan Bieńkiewicz; Hanna Romanowicz; Miłosz Wilczyński; Grzegorz Jabłoński; Anna Stepowicz; Anna Obłękowska; Andrzej Malinowski; Beata Smolarz
Journal:  BMC Cancer       Date:  2021-08-16       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.